These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 36213651)

  • 1. Host-directed therapies in pulmonary tuberculosis: Updates on anti-inflammatory drugs.
    Cubillos-Angulo JM; Nogueira BMF; Arriaga MB; Barreto-Duarte B; Araújo-Pereira M; Fernandes CD; Vinhaes CL; Villalva-Serra K; Nunes VM; Miguez-Pinto JP; Amaral EP; Andrade BB
    Front Med (Lausanne); 2022; 9():970408. PubMed ID: 36213651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Host-Directed Therapeutic Strategies for Tuberculosis.
    Kolloli A; Subbian S
    Front Med (Lausanne); 2017; 4():171. PubMed ID: 29094039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural products in anti-tuberculosis host-directed therapy.
    Huang X; Lowrie DB; Fan XY; Hu Z
    Biomed Pharmacother; 2024 Feb; 171():116087. PubMed ID: 38171242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammation-mediated tissue damage in pulmonary tuberculosis and host-directed therapeutic strategies.
    Tiwari D; Martineau AR
    Semin Immunol; 2023 Jan; 65():101672. PubMed ID: 36469987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies.
    Tiberi S; du Plessis N; Walzl G; Vjecha MJ; Rao M; Ntoumi F; Mfinanga S; Kapata N; Mwaba P; McHugh TD; Ippolito G; Migliori GB; Maeurer MJ; Zumla A
    Lancet Infect Dis; 2018 Jul; 18(7):e183-e198. PubMed ID: 29580819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in immunomodulatory strategies for host-directed therapies in combating tuberculosis.
    Ayodele S; Kumar P; van Eyk A; Choonara YE
    Biomed Pharmacother; 2023 Jun; 162():114588. PubMed ID: 36989709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Host-Directed Therapies for Tuberculosis.
    Jeong EK; Lee HJ; Jung YJ
    Pathogens; 2022 Nov; 11(11):. PubMed ID: 36365041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis.
    Zumla A; Rao M; Dodoo E; Maeurer M
    BMC Med; 2016 Jun; 14():89. PubMed ID: 27301245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Manipulation of autophagy for host-directed tuberculosis therapy.
    Gina P; Davids M; Dheda K
    Afr J Thorac Crit Care Med; 2019; 25(2):. PubMed ID: 34286250
    [No Abstract]   [Full Text] [Related]  

  • 11. Host Directed Therapies for Tuberculosis: Futures Strategies for an Ancient Disease.
    Palucci I; Delogu G
    Chemotherapy; 2018; 63(3):172-180. PubMed ID: 30032143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host-directed therapies for multidrug resistant tuberculosis.
    Zumla A; Maeurer M
    Int J Mycobacteriol; 2016 Dec; 5 Suppl 1():S21-S22. PubMed ID: 28043559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lactate Metabolism and Signaling in Tuberculosis and Cancer: A Comparative Review.
    Kiran D; Basaraba RJ
    Front Cell Infect Microbiol; 2021; 11():624607. PubMed ID: 33718271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Host-Directed Therapies for Tackling Multi-Drug Resistant Tuberculosis: Learning From the Pasteur-Bechamp Debates.
    Zumla A; Maeurer M;
    Clin Infect Dis; 2015 Nov; 61(9):1432-8. PubMed ID: 26219693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of host-directed therapies on the pathology of tuberculosis.
    Tsenova L; Singhal A
    J Pathol; 2020 Apr; 250(5):636-646. PubMed ID: 32108337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of anti-inflammatory agents as host-directed adjunct treatment of tuberculosis in humans: a systematic review and meta-analysis.
    Hayford FEA; Dolman RC; Blaauw R; Nienaber A; Smuts CM; Malan L; Ricci C
    Respir Res; 2020 Aug; 21(1):223. PubMed ID: 32847532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Host-Directed Therapy as a Novel Treatment Strategy to Overcome Tuberculosis: Targeting Immune Modulation.
    Ahmed S; Raqib R; Guðmundsson GH; Bergman P; Agerberth B; Rekha RS
    Antibiotics (Basel); 2020 Jan; 9(1):. PubMed ID: 31936156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid-Derived Suppressor Cells as Target of Phosphodiesterase-5 Inhibitors in Host-Directed Therapeutics for Tuberculosis.
    Leukes V; Walzl G; du Plessis N
    Front Immunol; 2020; 11():451. PubMed ID: 32269568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic Inhibition of Host Phosphodiesterase-4 Improves Isoniazid-Mediated Clearance of Mycobacterium tuberculosis.
    Subbian S; Koo MS; Tsenova L; Khetani V; Zeldis JB; Fallows D; Kaplan G
    Front Immunol; 2016; 7():238. PubMed ID: 27379099
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.